Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, for Aastrom Biosciences, Inc. (Note: The input metadata referenced "Vericel Corp," but the filing text explicitly identifies the registrant as Aastrom Biosciences, Inc.). Aastrom is a development-stage company focused on research and product development for ex vivo human cell production and gene therapy. The company operates in one reportable segment and has not yet achieved profitability, having accumulated losses of approximately $87.8 million since inception.
Key Financial Metrics
| Metric | Q3 2001 | Q3 2000 |
|---|---|---|
| Total Revenues | $151,000 | $167,000 |
| Net Loss | $(1,893,000) | $(1,406,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $10,660,000 | $3,764,000 |
| Short-term Investments | $4,508,000 | $0 |
| Total Liquid Assets | $15,168,000 | $3,764,000 |
| Research & Development Expenses | $1,207,000 | $1,020,000 |
| Operating Cash Flow | $(2,322,000) | $(1,289,000) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by $16,000 (approx. 10%) compared to the prior year quarter, driven entirely by a decrease in grant revenues from $167,000 to $151,000. Product sales and research agreements remained at zero for the quarter.
- Increased Expenses: Total costs and expenses rose to $2,166,000 from $1,782,000. This increase was primarily due to higher Research and Development (R&D) expenses ($187,000 increase) and Selling, General, and Administrative (SG&A) expenses ($157,000 increase).
- Inventory Write-down: The company recorded a $40,000 charge for the write-down of AastromReplicell inventory.
- Equity Financing: The company raised $6,841,000 through the issuance of 4,636,000 common shares under a shelf registration, completing the shares available under that offering. This significantly bolstered liquidity.
- Investment Activity: The company purchased $4,500,000 in short-term investments during the quarter, reflecting a shift in cash management strategy.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management states that available cash and expected interest income are sufficient to finance planned activities through the end of fiscal year 2002. However, the company expects to continue incurring significant operating losses and does not anticipate positive cash flow from operations for at least several years.
- Regulatory Status: The company has obtained CE Mark approval for its AastromReplicell System and specific kits (SC-I, CB-I, DC-I), allowing sales in Europe. However, U.S. commercialization requires FDA approval, which is not yet obtained. The company is conducting Phase I/II and Phase III clinical trials in the U.S.
- Key Risks:
- Funding Dependency: Future operations depend on obtaining additional funding through equity sales, debt, or strategic collaborations. Failure to secure funding could force substantial reductions in operations.
- Regulatory Approval: Failure to obtain FDA approval or demonstrate safety/efficacy in clinical trials would severely limit marketability.
- Third-Party Reliance: The company relies entirely on third parties for manufacturing components and supplies. Disruptions could halt clinical trials or sales.
- Market Acceptance: Even with approval, the market may not adopt the technology over standard bone marrow or blood stem cell transplant procedures.
- Unusual Items: The filing notes the resignation of the Vice President of Finance & Administration/CFO. Additionally, the company faces potential dilution from outstanding warrants and options.
Investor Verification Checklist
- Verify the status and timeline of ongoing Phase I/II and Phase III clinical trials in the U.S., specifically for the DC-I (cancer vaccine) and SC-I/CB-I (stem cell) products.
- Confirm the company's ability to secure additional financing beyond the end of fiscal year 2002, given the burn rate of approximately $2.3 million per quarter.
- Assess the progress of European commercialization activities following CE Mark approval and whether revenue from product sales is materializing.
- Review the terms of the University of Michigan patent licenses, which are critical to the company's technology and expire as early as 2012.
- Monitor the company's compliance with Nasdaq listing requirements, specifically regarding minimum bid price and tangible net worth, as the stock price has been volatile.